Fenwick Represents Underwriters in Belite Bio’s $350 Million Underwritten Public Offering

Fenwick represented the underwriters in Belite Bio, Inc’s (Nasdaq: BLTE) underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”) at a public offering price of $154.00 per ADS, for gross proceeds of approximately $350.0 million. Belite Bio, Inc. is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs. More information can be obtained from the news announcement.

The Fenwick transaction team included corporate partners Amanda Rose, Ryan Mitteness and Per Chilstrom and associates Christian Choi, Marianna Zabkowski and Guy Rotstein.